Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The company commercializes products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics and medicated feed additives. Zoetis has been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years.

• Employees: Approximately 14,100 (as of December 31, 2023)
• Geographic Footprint: Approximately 45 countries with products sold in more than 100 countries
• Headquarters: Parsippany, New Jersey
• Founded: July 2012 (incorporated)
• Number of manufacturing sites: 29
• Revenue: $8.544 billion (FY2023)
• Key Subsidiaries/Brands: VetScan, Alpha Ject, Simparica, Apoquel, Cytopoint, Revolution, Stronghold, Fostera, Librela

• CEO: Kristin C. Peck
• CFO: Wetteny Joseph
• President, Global Manufacturing and Supply: Nick Ashton
• President, U.S. Operations: Ester Banque
• Group President International Operations, Aquaculture and Global Diagnostics: Jamie Brannan
• General Counsel and Corporate Secretary; Business Lead of Human Health Diagnostics: Heidi C. Chen
• Head of Global Strategy, Commercial and Business Development, and Global BioDevices: Rimma Driscoll
• Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer: Jeannette Ferran Astorga
• Executive Vice President, Chief Human Resources Officer and Global Operations: Roxanne Lagano
• Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health: Wafaa Mamilli
• Executive Vice President and President, Research and Development: Robert J. Polzer

Key leaders have extensive experience in their respective fields.

• Annual Revenue: $8.544 billion (FY2023)
• Net Income: $2.344 billion (FY2023)
• Total Assets: $14.286 billion (as of December 31, 2023)
• Number of Employees: Approximately 14,100 (as of December 31, 2023)
• Key Financial Highlights: Revenue increased by 6% and net income increased by 11% compared to 2022.

Zoetis offers a diverse portfolio of animal health products.

• Parasiticides: Products that prevent or eliminate external and internal parasites.
• Vaccines: Biological preparations that help prevent diseases.
• Dermatology: Products that relieve itch associated with allergic conditions.
• Other Pharmaceutical: Pain and sedation, antiemetic, reproductive, and oncology products.
• Anti-infectives: Products that kill or slow the growth of bacteria, fungi or protozoa.
• Animal Health Diagnostics: Testing and analysis of blood, urine and other animal samples and related products and services.
• Medicated Feed Additives: Products added to animal feed that provide medicines to livestock.

Zoetis operates through two segments:

• United States (U.S.): 53% of total revenue for the year ended December 31, 2023.
• International: 46% of total revenue for the year ended December 31, 2023.
• Client Supply Services (CSS) and human health products: Approximately 1% of total revenue for the year ended December 31, 2023.

Zoetis's strategic priorities include:

• Leading through innovation across a diverse portfolio.
• Delivering an exceptional experience to delight customers.
• Powering the business through digital solutions and data insights.
• Supporting a workplace where colleagues can thrive.
• Advancing sustainability in animal health for a better future.
• Performing with excellence and agility.

Zoetis is the largest company based on revenue in the animal health industry. The company faces competition from other animal health companies, including Boehringer Ingelheim Animal Health Inc., Merck Animal Health, Elanco Animal Health and IDEXX Laboratories, as well as generic products and lower cost alternatives.

• Market Position: Largest based on revenue in the animal health industry.
• Key Competitors: Boehringer Ingelheim Animal Health Inc., Merck Animal Health, Elanco Animal Health, and IDEXX Laboratories.
• Industry Trends: Increasing pet ownership and spending on pet care, growing demand for animal protein, and consolidation in the animal health industry.

• Market Risks: Intense competition from existing and new companies, generic products, and lower-cost alternatives.
• Operational Risks: Dependence on key products, potential safety, quality or efficacy concerns, manufacturing and supply chain issues, and reliance on third-party suppliers.
• Financial Risks: Exposure to global economic and political conditions, foreign exchange rate fluctuations, and substantial indebtedness.
• Regulatory Risks: Compliance with animal health product regulations, data privacy laws, and environmental, health and safety laws.